886049-61-2

Basic information

• Product Name: 4-bromo-N-(cyclopropylmethyl)-2-nitroaniline
• Synonyms: 4-bromo-N-(cyclopropylmethyl)-2-nitroaniline
• CAS NO: 886049-61-2
• Molecular Weight: 271.114
• Mol File: 886049-61-2.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 4-bromo-N-(cyclopropylmethyl)-2-nitroaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-N-(cyclopropylmethyl)-2-nitroaniline(886049-61-2)
• EPA Substance Registry System: 4-bromo-N-(cyclopropylmethyl)-2-nitroaniline(886049-61-2)

Safety Data

• Hazardous Substances Data: 886049-61-2(Hazardous Substances Data)

Upstream product

• 364-73-8 4-Bromo-1-fluoro-2-nitrobenzene 
• 2516-47-4 cyclopropanemethylamine 
• 3460-18-2 1,4-dibromo-2-nitrobenzene 

Downstream Products

• 886049-63-4 5-bromo-1-(cyclopropylmethyl)-2-(2,2-dimethylpropyl)-1H-benzimidazole 
• 886049-62-3 4-bromo-N₁-(cyclopropylmethyl)benzene-1,2-diamine 

Relevant articles and documents

Rational Design of Original Fused-Cycle Selective Inhibitors of Tryptophan 2,3-Dioxygenase

Tryptophan 2,3-dioxygenase (TDO2) is a heme-containing enzyme constitutively expressed at high concentrations in the liver and responsible for l-tryptophan (l-Trp) homeostasis. Expression of TDO2 in cancer cells results in the inhibition of immune-mediated tumor rejection due to an enhancement of l-Trp catabolism via the kynurenine pathway. In the study herein, we disclose a new 6-(1H-indol-3-yl)-benzotriazole scaffold of TDO2 inhibitors developed through rational design, starting from existing inhibitors. Rigidification of the initial scaffold led to the synthesis of stable compounds displaying a nanomolar cellular potency and a better understanding of the structural modulations that can be accommodated inside the active site of hTDO2.

Optimisation of a novel series of selective CNS penetrant CB2 agonists

A series of benzimidazole CB2 receptor agonists were prepared and their properties investigated. Optimisation of the three benzimidazole substituents led to the identification of compound 23, a potent CB2 full agonist (EC50/sub

N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY

This invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R1, R2,R3, R4, R5, R6, R7, k, m, n, p, q, r and s are each as described herein, and compositions containing such compounds, and the use of such compounds in the treatment of a condition mediated by CB2 receptor activity.